- Home
- TLSI vs ABOS Comparison
TLSI vs ABOS Comparison
Compare TLSI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- ABOS
- Stock Information
- Founded
- TLSI 2010
- ABOS 1996
- Country
- TLSI United States
- ABOS United States
- Employees
- TLSI N/A
- ABOS N/A
- Industry
- TLSI Medical Specialities
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- ABOS Health Care
- Exchange
- TLSI Nasdaq
- ABOS Nasdaq
- Market Cap
- TLSI 204.0M
- ABOS 72.7M
- IPO Year
- TLSI N/A
- ABOS 2021
- Fundamental
- Price
- TLSI $5.00
- ABOS $1.49
- Analyst Decision
- TLSI Strong Buy
- ABOS Strong Buy
- Analyst Count
- TLSI 5
- ABOS 4
- Target Price
- TLSI $10.90
- ABOS $6.50
- AVG Volume (30 Days)
- TLSI 154.7K
- ABOS 623.5K
- Earning Date
- TLSI 08-13-2025
- ABOS 08-12-2025
- Dividend Yield
- TLSI N/A
- ABOS N/A
- EPS Growth
- TLSI N/A
- ABOS N/A
- EPS
- TLSI N/A
- ABOS N/A
- Revenue
- TLSI $32,141,000.00
- ABOS N/A
- Revenue This Year
- TLSI $55.52
- ABOS N/A
- Revenue Next Year
- TLSI $54.76
- ABOS N/A
- P/E Ratio
- TLSI N/A
- ABOS N/A
- Revenue Growth
- TLSI 46.20
- ABOS N/A
- 52 Week Low
- TLSI $3.50
- ABOS $0.86
- 52 Week High
- TLSI $6.04
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- TLSI 42.89
- ABOS 58.51
- Support Level
- TLSI $4.85
- ABOS $1.12
- Resistance Level
- TLSI $5.11
- ABOS $1.27
- Average True Range (ATR)
- TLSI 0.30
- ABOS 0.06
- MACD
- TLSI -0.03
- ABOS 0.00
- Stochastic Oscillator
- TLSI 13.45
- ABOS 77.78
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.